Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Methoxy polyethylene glycol-epoetin beta 50microg/0.3ml inj
0901030N0AAAAAA
|
MPEG-Epoetin Beta | Methoxy polyethylene glycol-epoetin beta | Nutrition and Blood | 5 |
|
Methoxy polyethylene glycol-epoetin beta 150microg/0.3ml inj
0901030N0AAADAD
|
MPEG-Epoetin Beta | Methoxy polyethylene glycol-epoetin beta | Nutrition and Blood | 4 |
|
Methoxy polyethylene glycol-epoetin beta 120microg/0.3ml inj
0901030N0AAAHAH
|
MPEG-Epoetin Beta | Methoxy polyethylene glycol-epoetin beta | Nutrition and Blood | 2 |
|
Methoxy polyethylene glycol-epoetin beta 30microg/0.3ml inj
0901030N0AAAGAG
|
MPEG-Epoetin Beta | Methoxy polyethylene glycol-epoetin beta | Nutrition and Blood | 2 |
|
Methoxy polyethylene glycol-epoetin beta 100microg/0.3ml inj
0901030N0AAACAC
|
MPEG-Epoetin Beta | Methoxy polyethylene glycol-epoetin beta | Nutrition and Blood | No data available |
|
Methoxy polyethylene glycol-epoetin beta 200microg/0.3ml inj
0901030N0AAAEAE
|
MPEG-Epoetin Beta | Methoxy polyethylene glycol-epoetin beta | Nutrition and Blood | No data available |
|
Methoxy polyethylene glycol-epoetin beta 250microg/0.3ml inj
0901030N0AAAFAF
|
MPEG-Epoetin Beta | Methoxy polyethylene glycol-epoetin beta | Nutrition and Blood | No data available |
|
Methoxy polyethylene glycol-epoetin beta 360microg/0.6ml inj
0901030N0AAAIAI
|
MPEG-Epoetin Beta | Methoxy polyethylene glycol-epoetin beta | Nutrition and Blood | No data available |
|
Methoxy polyethylene glycol-epoetin beta 75microg/0.3ml inj
0901030N0AAABAB
|
MPEG-Epoetin Beta | Methoxy polyethylene glycol-epoetin beta | Nutrition and Blood | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.